AMENDMENT NO. 1

Company

Zentalis Pharmaceuticals, Inc.

Filed

February 14, 2022

Accession Number

0000929638-22-000451

A Schedule 13G is filed when a passive investor acquires more than 5% of a company's shares without intent to influence control. Learn more about SC 13G filings →